Sofinnova Partners Closes MD Start IV Fund at €82 Million

Sofinnova Partners has closed its MD Start IV fund at €82 million, according to a report by Pulse 2.0. The close marks the fourth iteration of the firm's MD Start program and adds a fresh pool of dedicated capital to Sofinnova's early-stage life sciences franchise.

The figure is the hardest number in the story: €82 million in committed capital, now ready for deployment. Sofinnova Partners, a European venture firm with a decades-long track record in biotech and medtech, has used the MD Start series to build companies from the ground up — typically around promising medical technologies and founding teams rather than around existing startups seeking growth capital.

What is the MD Start strategy?

MD Start sits in the venture-building corner of Sofinnova's platform. Instead of leading rounds in companies that already exist, the program creates new companies around identified opportunities — often in medtech — and shepherds them from concept through early clinical and regulatory milestones.

The approach targets a specific gap in European life sciences financing: the stage between an academic or inventor-side breakthrough and the point at which a conventional Series A investor will commit. By writing the first institutional cheque itself, Sofinnova can control company formation decisions, assemble management, and shape asset strategy before outside capital enters the cap table.

A fourth fund in the series signals that the model has retained investor confidence across cycles. Successive closes of a venture-building vehicle suggest limited partners saw returns or strategic value in the earlier MD Start funds sufficient to re-up.

Why does an €82 million close matter?

In the current environment, the number is meaningful in three ways.

• It is dedicated, ring-fenced capital. The €82 million sits outside Sofinnova's flagship funds, meaning the firm can take formation-stage risk without competing for deployments against later-stage mandates.
• It signals appetite for early-stage medtech. European venture fundraising has tightened since 2022. A closed formation-stage fund indicates limited partners are still willing to back pre-company risk in life sciences.
• It extends a repeatable process. A fourth vintage implies a pipeline discipline: the firm can run multiple builds in parallel and recycle learnings — regulatory strategy, trial design, team placement — across the portfolio.

The size also sets expectations. At €82 million, MD Start IV can support a portfolio of seed and formation-stage positions, with each new company likely receiving enough capital to reach value-inflection milestones that attract follow-on investors.

What comes next?

The immediate question is deployment. A closed fund is a promise, not yet a portfolio. Watch for first-announce deals out of MD Start IV over the coming quarters — the sectors, geographies, and founding teams Sofinnova backs first will show where the firm sees the sharpest opportunity in medical technology formation.

The close also positions Sofinnova to keep pace with a broader shift in European life sciences venture, where dedicated build-and-incubate vehicles have grown in prominence as traditional seed funding for hardware-adjacent and device plays has thinned. Whether MD Start IV's €82 million translates into durable companies will depend on execution — but the capital to attempt it is now in place.